A cross-sectional survey of HIV genotype mutations conferring resistance to all nonnucleoside reverse transcriptase inhibitors and related features, at the time of failure of antiretroviral therapy in the real world [1] (multiple letters)

Journal of Acquired Immune Deficiency Syndromes

Volumn 28, Issue 1, 2001, Pages 97-99

  Manfredi, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; ANTIBIOTIC RESISTANCE; CHILD; GENETICS; MUTATION; PREVALENCE; VIROLOGY;

ADOLESCENT; ADULT; AGED; CHILD; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMAN; MALE; MIDDLE AGE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0035455049     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200109010-00015     Document Type: Letter

References (16)

1. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogue and protease inhibitors
2. Clinical uses of non-nucleoside reverse transcriptase inhibitors
3. Antiretroviral drug resistance testing in adults with HIV infection: Implication for clinical management
4. Efavirenz: Resistance and cross-resistance
5. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
6. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial
7. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
8. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
9. Quantification of the impact of HIV-1 reverse transcriptase mutations on the efficacy of rescue HAART
10. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine
11. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor in heavily pre-treated HIV-infected patients
12. Genotypic and phenotypic nevirapine resistance correlates with failure during salvage therapy including abacavir and nevirapine
13. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
14. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up
15. Expanded-spectrum non-nucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1
16. Incomplete genotypic resistance to nonnucleoside reverse transcriptase inhibitors in patients treated with nevirapine: A potential interest in clinical practice